INFI · Infinity Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $583.0K | $731.0K | - | $712.0K | $686.0K | $652.0K | - | $428.0K | $512.0K | $467.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.60M | $5.85M | - | $7.66M | $8.79M | $8.99M | - | $7.07M | $7.96M | $8.20M |
| SG&A | $3.75M | $5.94M | - | $3.50M | $3.50M | $3.68M | - | $3.85M | $3.50M | $3.57M |
| Total Operating Expenses | $10.70M | $12.24M | - | $11.59M | $12.70M | $13.06M | - | $11.18M | $11.76M | $12.05M |
| D&A | - | $105.0K | - | - | - | $121.0K | - | - | - | $119.0K |
| Operating Income | ($10.12M) | ($11.51M) | - | ($10.88M) | ($12.02M) | ($12.41M) | - | ($10.75M) | ($11.25M) | ($11.58M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($9.96M) | ($11.04M) | - | ($10.72M) | ($11.99M) | ($12.44M) | - | ($10.71M) | ($11.27M) | ($11.63M) |
| EPS - Basic | ($0.11) | ($0.12) | - | ($0.12) | ($0.13) | ($0.14) | - | ($0.12) | ($0.16) | - |
| EPS - Diluted | ($0.11) | ($0.12) | - | ($0.12) | ($0.13) | ($0.15) | - | ($0.12) | ($0.13) | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.75M | $25.74M | $38.31M | $47.18M | $45.84M | $53.13M | $80.73M | $90.09M | $97.26M | $106.76M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.50M | $1.94M | $4.41M | $1.95M | $1.81M | $2.00M | $2.32M | $1.80M | $954.0K | $1.21M |
| Current Assets | $19.91M | $28.36M | $40.30M | $49.35M | $59.61M | $70.10M | $82.27M | $91.93M | $99.68M | $109.31M |
| Total Assets | $21.23M | $29.95M | $42.15M | $51.59M | $61.86M | $72.58M | $84.78M | $94.61M | $102.60M | $112.40M |
| Current Liabilities | $12.06M | $11.29M | $13.63M | $14.20M | $14.34M | $13.39M | $13.30M | $12.35M | $10.55M | $9.46M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $58.64M | $58.27M | $61.20M | $62.47M | $62.96M | $62.60M | $63.21M | $62.47M | $61.06M | $60.35M |
| Stockholders' Equity | ($37.41M) | ($28.32M) | ($19.05M) | ($10.87M) | ($1.11M) | $9.98M | $21.57M | $32.14M | $41.54M | $52.05M |
| Retained Earnings | ($876.95M) | ($867.00M) | ($855.95M) | ($846.72M) | ($836.00M) | ($824.02M) | ($811.58M) | ($799.93M) | ($789.22M) | ($777.95M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($12.58M) | - | - | - | ($13.54M) | - | - | - | ($13.47M) |
| Investing Cash Flow | - | $0 | - | - | - | ($14.07M) | - | - | - | $5.50M |
| Financing Cash Flow | - | - | - | - | - | $0 | - | - | - | $86.13M |
| CapEx | - | $0 | - | - | - | $17.0K | - | - | - | $0 |
| Free Cash Flow | - | ($12.58M) | - | - | - | ($13.55M) | - | - | - | ($13.47M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -1735.8% | -1574.1% | - | -1528.2% | -1751.9% | -1902.9% | - | -2511.7% | -2197.5% | -2480.1% |
| EBITDA margin | - | -1559.8% | - | - | - | -1884.4% | - | - | - | -2454.6% |
| Net margin | -1707.7% | -1510.9% | - | -1505.2% | -1747.2% | -1907.4% | - | -2503.0% | -2201.0% | -2490.1% |
| Free cash flow margin | - | -1720.4% | - | - | - | -2078.5% | - | - | - | -2884.4% |
| FCF / Net income | - | 1.14 | - | - | - | 1.09 | - | - | - | 1.16 |
| R&D / Revenue | 1131.6% | 800.7% | - | 1076.3% | 1282.1% | 1378.8% | - | 1652.6% | 1554.1% | 1756.1% |
| SG&A / Revenue | 643.9% | 813.1% | - | 491.7% | 509.5% | 563.8% | - | 898.8% | 683.2% | 763.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -46.9% | -36.9% | - | -20.8% | -19.4% | -17.1% | - | -11.3% | -11.0% | -10.3% |
| Return on equity | 26.6% | 39.0% | - | 98.6% | 1082.7% | -124.6% | - | -33.3% | -27.1% | -22.3% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.65 | 2.51 | 2.96 | 3.48 | 4.16 | 5.23 | 6.19 | 7.44 | 9.44 | 11.56 |
| Quick ratio | 1.65 | 2.51 | 2.96 | 3.48 | 4.16 | 5.23 | 6.19 | 7.44 | 9.44 | 11.56 |
| Cash ratio | 1.47 | 2.28 | 2.81 | 3.32 | 3.20 | 3.97 | 6.07 | 7.29 | 9.22 | 11.29 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.57 | -1.06 | -2.21 | -4.74 | -55.88 | 7.27 | 3.93 | 2.94 | 2.47 | 2.16 |
| Liabilities / Assets | 2.76 | 1.95 | 1.45 | 1.21 | 1.02 | 0.86 | 0.75 | 0.66 | 0.60 | 0.54 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | 0.02 | - | 0.01 | 0.01 | 0.01 | - | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -15.0% | 12.1% | - | 66.4% | 34.0% | 39.6% | - | -13.7% | 42.2% | 9.1% |
| Revenue CAGR (3y) | 17.4% | 19.5% | - | -68.1% | 38.7% | -32.7% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 15.8% | 7.3% | - | -1.2% | -6.8% | -7.1% | - | -21.5% | -26.1% | -10.3% |
| Net income growth (YoY) | 16.9% | 11.2% | - | -0.0% | -6.4% | -6.9% | - | -12.4% | -19.0% | -6.8% |
| EPS growth (YoY) | 15.4% | 20.0% | - | 0.0% | 0.0% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 7.2% | - | - | - | -0.6% | - | - | - | -14.2% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -3279.0% | - | - | - | - | -80.8% | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Product / service
$1.72M totalRoyalty$1.72M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing INFINITY PHARMACEUTICALS against the 5 most active filers in the same SIC group.